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Abstract
People with chronic epilepsy (PWE) often make costly, and clinically unnecessary emergency department (ED) visits. Some
do it frequently. No studies have examined interventions to reduce them. An intervention delivered by an epilepsy nurse
specialist (ENS) might reduce visits. The rationale is it may optimize patients’ self-management skills and knowledge of
appropriate ED use. We examined such an intervention’s clinical- and cost-effectiveness. Eighty-five adults with epilepsy
were recruited from three London EDs with similar catchment populations. Forty-one PWE recruited from two EDs received
treatment-as-usual (TAU) and formed the comparison group. The remaining 44 PWE were recruited from the ED of a
hospital that had implemented a new ENS service for PWE attending ED. These participants formed the intervention group.
They were offered 2 one-to-one sessions with an ENS, plus TAU. Participants completed questionnaires on health service use
and psychosocial well-being at baseline, 6- and 12-month follow-up. Covariates were identified and adjustments made.
Sixty-nine (81%) participants were retained at follow-up. No significant effect of the intervention on ED visits at 12 months
or on other outcomes was found. However, due to less time as inpatients, the average service cost for intervention
participants over follow-up was less than for TAU participants’ (adjusted difference £558, 95% CI, 2£2409, £648). Covariates
most predictive of subsequent ED visits were patients’ baseline feelings of stigmatization due to epilepsy and low
confidence in managing epilepsy. The intervention did not lead to a reduction in ED use, but did not cost more, partly
because those receiving the intervention had shorter hospital admissions. Our findings on long-term ED predictors clarifies
what causes ED use, and suggests that future interventions might focus more on patients’ perceptions of stigma and on
their confidence in managing epilepsy. If addressed, ED visits might be reduced and efficiency-savings generated.
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Introduction
Epilepsy is a common neurological disorder, with an annual
incidence rate of 50–55 per 100,000 person-years [1]. It is also
costly. The cost per case in the EU in 2004 was J2,000–11,500
per annum [2]. Studies from around the world show people with
epilepsy (PWE) frequently use expensive hospital emergency
services [3–5]. This helps explain why health costs are so high [6].
Some of the clearest evidence on ED use comes from the U.K.,
where the prevalence of active epilepsy is approximately 5 cases
per 1000 people [1]. Each year, around a fifth of all PWE in the
U.K. visit a hospital emergency department (ED) [7,8]. Approx-
imately one half of these visits result in the patient being admitted
[8,9]. Costs are further increased by PWE visiting ED repeatedly.
Around 60% of PWE who attend ED do so on multiple occasions
within a 12-month period [10]. The estimated cost of providing
emergency care for epilepsy in the U.K. in 2010/11 was
£47 million [11,12].
In addition to being costly, ED visits by PWE are often clinically
unnecessary. The majority of ED visits are by those with known,
rather than new epilepsy [7,9] and one of their commonest
presentations is that of an uncomplicated seizure [9]. In such
instances, emergency medical care is not recommended [13].
Evidence from the U.K.’s National Audit of Seizure Management
in Hospitals (NASH) also suggests that ED use has little added
value for the care of PWE [7].
What may be important to reducing ED visits by PWE is their
ability to self-manage their epilepsy. Coping with life in the context
of having epilepsy requires PWE to accept their diagnoses and
adopt self-management behaviors to prevent seizures and manage
consequences. This includes taking anti-epileptic drugs (AEDs),
identifying and managing seizure triggers, implementing precau-
tions to minimize risk, telling others what to do when a seizure
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occurs, and learning what to do during recovery. Evidence, mainly
from cross-sectional surveys, suggests ED visits by PWE are often
associated with a failure to master such tasks [10,14,15].
What intervention could improve the self-management skills of
PWE who visit ED and who should deliver it is currently
unknown. An educational intervention aiming to promote self-
management skills, delivered by epilepsy nurse specialists (ENS) to
PWE, is one possibility. Case-series suggest nurse interventions
may reduce emergency visits [16,17]. Furthermore, trials testing
ENS interventions in the wider epilepsy population shows they can
lead to improvements in domains potentially relevant to ED use,
including patients’ epilepsy knowledge [18].
In the present study (ISRCTN06469947) we test the hypothesis
that compared to treatment-as-usual (TAU) alone, an ENS-led
self-management intervention can reduce reattendance at ED and
improve well-being. To do this, we recruited PWE who had
attended the EDs of three inner London hospitals with similar
catchment populations but which had started to implement
different care pathways for PWE. One hospital offered PWE
attending their ED access to a new ENS service, whilst the other
two hospitals did not. We compared the outcomes of patients and
completed an economic evaluation of the services.
Methods
Design
Adults attending the EDs for established epilepsy were
prospectively recruited (May 2009 – March 2011). Patients
recruited from the ED of King’s College Hospital (KCH) were
offered the new ENS intervention, plus TAU, whilst those
recruited from the EDs of St. Thomas’ Hospital (STH) and
University Hospital Lewisham (UHL) were offered TAU. We have
previously described how attendances were identified and
participants’ representativeness [10].
Recruitment sites
Together, the three EDs serve one million residents in the
London boroughs of Southwark, Lambeth and Lewisham where
epilepsy prevalence in adults is 0.51% [19]. The EDs and the
populations they predominantly serve, are similar, making
comparison of their patients’ outcomes reasonable [19–21].
Inclusion criteria
Patients were eligible to participate if they: were aged $18; had
a documented diagnosis of epilepsy for$1 year; could independently
Table 1. Details of the Epilepsy Nurse-Specialist (ENS) led self-management intervention.
Aspect of intervention Details
Premise N PWE, as opposed to medical care providers, are responsible for their day-to-day epilepsy management. As such, PWE
need the knowledge, support and skills to mitigate disability and improve outcome
N Aimed to reduce ED visits by optimizing patients’ self-management skills and knowledge of appropriate ED use.
Content N Two one-to-one sessions with an ENS.
N To guide the intervention’s delivery and record information given and actions taken by the ENS during sessions, a
comprehensive checklist was developed (available from authors on request).
N Intervention started with the ENS reviewing the patient’s epilepsy and checking that the AED(s) and dosing the
patient reported taking was consistent with prescription.
N Information provision formed large component. The areas on which information could be provided included:
epilepsy’s causes; seizure first aid; the role and mechanisms of AEDs; the importance of adherence and the taking of the
same brand; prescription charges; about what to do if a dose is missed; seizure triggers; safety in the home; legal rights
of, and benefits available for, PWE epilepsy; and the contact details of support organisations.
N The ENS informed patients about the names of their seizures and syndrome and having reviewed their existing
medical records, probable cause.
N With regards advice concerning seizure first aid, the ENS the informed the patient what should and should not be
done when a seizure occurs and, as a permanent record, provided the patient with an information pamphlet on first aid
management of seizures developed by the U.K.’s National Society for Epilepsy [14]. As per these guidelines, participants
were informed that when a person with established epilepsy has an epileptic seizure there is usually no need to call an
ambulance. For such PWE, emergency medical care was recommended only when any of the following applied: (i) they
had sustained a significant injury; (iii) had trouble breathing after the seizure had stopped; (iv) when one seizure
immediately followed another with no recovery in between; (v) when the seizure lasted two minutes longer than was
usual for them; or the seizure lasts for more than five minutes and it was not known how long their seizures usually last.
N The ENS developed personalized care plans with the patient, helped them set goals (e.g., to socialize more, be
comfortable talking about epilepsy, and less fearful about seizures), evaluated progress and provided the patient with
the opportunity to ask questions.
N The ENS could make referrals, tailored to the patients’ requirements, by normal pathways to other services (e.g.,
counselling, social services, and emergency rescue medication clinic). Any advice given and actions taken were
communicated to the patient’s primary care doctor.
N At appointments, participants had direct access to either of two ‘‘Expert Patients’’ in the waiting room who were
trained by the U.K.’s National Society for Epilepsy, and were invited to join a service users’ group.
N Carers accompanied patients when PWE requested this.
Those delivering intervention N Sessions were delivered by either one of the two ENSs based at KCH.
N Before the implementation of this new service, for reasons of limited service capacity, the ENSs only accepted direct
referrals from neurologists and neurosurgeons. They ran clinics, but, as was the case this new service, did not
independently prescribe AEDs. One had 8 years of experience working as an ENS and the other 10.
NotesRAED= antiepileptic drug; ED= emergency department; ENS = Epilepsy Nurse Specialist; KCH= King’s College Hospital; PWE= people with epilepsy.
doi:10.1371/journal.pone.0090789.t001
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complete questionnaires; had no life-threatening or serious co-
morbidity; had not seen an ENS in the prior year; had not been
referred by ED to Neurology for outpatient care; and resided within
Lambeth, Southwark, or Lewisham.
Ethics Statement
The Joint South London and Maudsley and the Institute of
Psychiatry NHS Research Ethics Committee approved the study
(08/H0807/86). All participants provided written informed consent.
Treatment groups
ENS intervention (plus TAU) group. The ENS intervention
consisted of those attending KCH ED being offered 2 one-to-one
sessions delivered on an outpatient basis at KCH. Initial sessions
were to last 45–60 minutes and the second 30 minutes. The
intervention was planned to be responsive to a patient’s individual
needs, so the number of sessions completed was permitted to vary.
The intervention was informed by the premise that PWE are
responsible for their epilepsy’s day-to-day management. As such,
the ENS was to provide PWE with the knowledge, support and
skills to mitigate disability and improve outcome [22]. Table 1
provides details.
TAU group. Following recruitment, no restrictions were
placed on the services TAU participants could access. In the
U.K., there is no accepted care for those with established epilepsy
who have visited an ED. All PWE are though expected to have a
medical review of their epilepsy at least yearly by a generalist or
specialist. When seizures are not controlled or treatment fails, it is
expected that a patient will be referred to secondary or tertiary
services [23]. The U.K.’s NASH showed EDs initiate referral to
neurology for only a third of PWE attending ED [9]. At the time of
the study, no ENS services were part of TAU at STH or UHL.
Baseline and outcome measures
Participants were assessed at three points using validated
questionnaires: baseline (assessment 1), 6- (assessment 2) and 12-
months post recruitment (assessment 3). For assessments 1 and 2,
measures were completed face-to-face. Assessment 3 was com-
pleted by post.
Clinical outcomes. These included self-report measures for
epilepsy-related ED use [24] and patient well-being [25]. The
latter included epilepsy-specific quality of life (QoL) [31], seizure
frequency [26–28], medication management skills [29], psycho-
logical distress [30], felt stigma [31], confidence in managing
epilepsy (i.e., mastery) [32] and epilepsy knowledge [33]. Table S1
details the questionnaires and gives example items.
Cost-effectiveness. This evaluation primarily adopted a
healthcare perspective with the cost of providing care for
participants in the two treatment groups over follow-up being
compared. The cost of lost employment was included in further
analyses.
To ascertain health-care costs, participants reported health
service use on the Client Service Receipt Inventory (CSRI) [24] at
baseline and at follow-up assessments. The CSRI referred to the
previous 12 months at assessment 1 and the previous 6 months at
assessments 2 and 3. Table S1 describes the CSRI. Costs were
calculated by combining service use data with appropriate national
unit costs [34]. The epilepsy nurse cost was estimated at £50 per
hour. This takes into account salaries, overheads, capital costs,
training, and the ratio of direct to indirect contact time.
To promote the comparison of interventions between studies, a
generic outcome measure should be incorporated into economic
evaluations [35]. We used the most common method, the quality-
adjusted life year (QALY). A QALY adjusts time spent in a health
state by a utility score anchored by 1 (full health) and 0 (death).
The European Quality of Life-5 Dimensions (EQ-5D) [36], the
measure favoured by decision makers in England and other
countries, combined with U.K. weights [37], was used to generate
utility scores at baseline and follow-up. Area under the curve
methods were then used to estimate the QALYs gained during the
follow-up period.
Sample size
The primary outcome measure was ED visits. No evidence
existed on what sort of effect the intervention might have on these.
Jacoby et al. [4] found 27% of PWE in the U.K. with uncontrolled
epilepsy make at least one ED visit per year. We hypothesized that
the ENS intervention might reduce re-attendance to 7% (Rate
Ratio 0.26), partly by more effective self-management, partly by
more frequent and appropriate use of non-emergency services.
Following Parmar and Machin’s [38] formulae, two groups of 60
would give 80% power to detect such a difference. We planned to
recruit 160 participants into our study in order to allow for 25%
loss to follow-up. It was considered that a reduction of 20%
(number needed to treat 5) would be needed if the intervention
was to gain general acceptability.
Statistical analyses
Treatment group equivalence and care received. Descriptive
statistics describe the characteristics of those recruited into the
treatment groups, those retained at follow-up and the epilepsy care
they received. Logistic regression tested for the significance of any
differences between the groups. Odds-ratios (OR) and 95%
confidence intervals (CI) are presented.
Effect of ENS intervention on clinical outcomes. The
primary outcome was the number of ED visits participants
reported making over the 6 months preceding assessment 3.
Secondary measures were the number of visits made over the
6 months preceding assessment 2 and patient well-being at
assessments 2 and 3.
The analyses of the effect of the intervention on each of the
outcome measures were performed using an intention-to-treat
(ITT) approach. To further understand any treatment effects,
efficacy based comparisons were also completed. These included
in the intervention group only those participants who had received
at least one intervention session. For all analyses, participants from
the two non-intervention sites were pooled to form one single
TAU group.
Effect on ED use. To compare the ENS intervention’s effect
on ED use to TAU alone, negative binomial regression (NBR) was
used to determine if treatment group predicted ED visits over
follow-up. Over dispersion of ED visits meant NBR, with robust
standard errors, was appropriate [39]. A P-value of ,0.05 was
considered statistically significant.
Unadjusted NBR analyses were first completed. However, to
account for imbalances between treatment groups in baseline
characteristics, we also completed adjusted NBR. This involved
first examining the association between scores on each baseline
measure and ED visits at assessments 2 and 3. Covariates with a
marginal association (P,0.10) were then included in the
applicable adjusted analyses. The adjustments made for each
model are indicated in the table notes.
Treatment effect estimates are presented as incidence rate-ratios
(IRRs), with 95% CIs. IRRs less than 1 represent a lower visit rate
in the ENS treatment group relative to TAU, whilst IRRs greater
than 1, indicate a higher rate.
Effect on patient well being. Scores on the measures of
patient well-being were treated as continuous and linear regression,
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with robust standard errors, tested for treatment effects. Results
from unadjusted and adjusted analyses are presented. Treatment
effect estimates are presented in the form of unstandardized
coefficients.
Cost-effectiveness. Total service costs of the two groups at
the follow-up assessment points were compared using linear
regression with adjustment for baseline cost. Bootstrapped 95%
CIs were generated around the regression coefficient representing
the cost difference.
Healthcare costs were combined with QALY data in the form of
an incremental cost-effectiveness ratio (ICER), calculated by
dividing the incremental costs for the ENS treatment group
compared to the comparison group by the incremental QALY
gain. To address uncertainty around the ICER, we generated
1000 resamples using bootstrapping with replacement and
calculated cost and outcome differences for each resample. These
1000 cost-outcome pairs were plotted on to a cost-effectiveness
plane.
All analyses were performed using STATA 11 (Stata Corpora-
tion, College Station, TX, U.S.A.)
Results
Participants
Recruitment and treatment group equivalence at
baseline. Three hundred and fifteen eligible PWE were iden-
tified and 85 agreed to participate. Figure 1 depicts recruitment
and retention. Mean participant age was 41 (SD = 16) and 53%
were male. Median years since diagnosis was 11 (interquartile
range [IQR] = 6–28).
Forty-four participants formed the ENS treatment group and 41
the TAU comparison group. At assessment 1 (baseline), the two
groups were similar (Table 2). The TAU group did, however,
report having experienced more seizures in the previous year.
Their median seizure number was 10 (IQR = 1.2–4.5) compared
to 5.5 (IQR = 1.0–3.0) for participants in the ENS treatment
group.
Retention at follow-up. Sixty-nine (81%) participants were
retained at assessments 2 and 3. This included 37 (90%)
participants from the TAU group and 32 (73%) participants from
the ENS group. It is on these participants that ITT analyses were
based.
Figure 1. Flow diagram of participant recruitment, treatment allocation and retention. Note to Figure 1: * Participant died of sudden
unexplained death in epilepsy. This patient was allocated to the intervention study arm, but failed to attend all offers of appointments prior to death.
doi:10.1371/journal.pone.0090789.g001
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Table 2. Baseline characteristics of study participants according to treatment group and assessment.
Baseline measure (n/ %) Treatment groups at baseline
TAU group (n = 41) ENS group (n = 44) OR (95% CI)
Age at baseline
18–24 6 (14.6) 8 (18.2) 1.00 Reference
25–34 8 (19.5) 12 (27.3) 1.55 (0.56, 4.31)
35–45 7 (17.1) 7 (15.9) 0.92 (0.29, 2.91)
46–53 12 (29.3) 8 (18.2) 0.54 (0.19, 1.50)
54–89 8 (19.5) 9 (20.5) 1.06 (0.36, 3.09)
Gender
Male 22 (53.7) 24 (54.5) 1.00 Reference
Female 19 (46.3) 20 (45.5) 0.97 (0.41, 2.28)
Ethnicity
Other 17 (41.5) 17 (38.6) 1.00 Reference
White British 24 (58.5) 27 (61.4) 0.89 (0.37, 2.13)
Years of formal education
10 Least educated 2 (4.9) 1 (2.3) 1.00 Reference
11 24 (58.5) 19 (43.2) 0.54 (0.23, 1.28)
12 2 (4.9) 2 (4.5) 0.93 (0.12, 7.00
13–15.5 6 (14.6) 10 (22.7) 1.72 (0.56, 5.28)
16–24 Most educated 7 (17.1) 12 (27.3) 1.82 (0.63, 5.24)
Deprivation score
13.97–22.70 Least deprived 5 (12.2) 12 (27.3) 1.00 Reference
23.36–28.98 9 (22.0) 8 (18.2) 0.79 (0.27, 2.31)
29.75–33.46 7 (17.1) 10 (22.7) 1.43 (0.48, 4.22)
33.56–38.31 11 (26.8) 7 (15.9) 0.52 (0.18, 1.50)
38.76–47.46 Most deprived 9 (22.0) 7 (15.9) 0.67 (0.22, 2.02)
Co-morbidity
None 23 (56.1) 20 (45.5) 1.00 Reference
Psychiatric and/or medical 18 (43.9) 24 (54.5) 1.53 (0.65, 3.63)
Years epilepsy diagnosed
2–4 5 (12.2) 10 (22.7) 1.00 Reference
5–8 9 (22.0) 7 (15.9) 0.67 (0.22, 2.02)
9–15 7 (17.1) 13 (29.5) 2.04 (0.72, 5.80)
16–34 9 (22.0) 8 (18.2) 0.79 (0.27, 2.31)
35–67 11 (26.8) 6 (13.6) 0.43 (0.14, 1.31)
ED visits prior 12 months
1 15 (36.6) 18 (40.9) 1.00 Reference
2 12 (29.3) 10 (22.7) 0.71 (0.27, 1.90)
3–4 3 (7.3) 8 (18.2) 2.82 (0.69, 11.55)
5–25 11 (26.8) 8 (18.2) 0.61 (0.22, 1.71)
Seizures prior 12 months
1–2 7 (17.1) 10 (22.7) 1.00 Reference
3–5 6 (14.6) 12 (27.3) 2.19 (0.73, 6.56)
6–9 6 (14.6) 8 (18.2) 1.30 (0.41, 4.15)
10 or more 22 (53.7) 14 (31.8) 0.40 (0.17, 0.98)
Seizure severity score
0–5 Least severe 13 (32.5) 20 (45.5) 1.00 Reference
7.5–50 10 (25) 6 (13.6) 0.47 (0.15, 1.46)
52.5–67.5 9 (22.5) 8 (18.2) 0.77 (0.26, 2.24)
70–90 Most severe 8 (20) 10 (22.7) 1.18 (0.41, 3.38)
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Table 2. Cont.
Baseline measure (n/ %) Treatment groups at baseline
TAU group (n = 41) ENS group (n = 44) OR (95% CI)
Seizure onset
Generalized or unknown 19 (46.3) 17 (38.6) 1.00 Reference
Focal 22 (53.7) 27 (61.4) 1.37 (0.58, 3.27)
AEDS prescribed
0 1 (2.4) 2 (4.5) 1.00 Reference
1 18 (43.9) 26 (59.1) 1.85 (0.78, 4.39)
2 16 (39.0) 13 (29.5) 0.66 (0.27, 1.62)
3–5 6 (14.6) 3 (6.8) 0.43 (0.10, 1.85)
Depression score
0–1 Least symptoms 11 (26.8) 2 (4.5) 1.00 Reference
2–3 11 (26.8) 26 (59.1) 0.70 (0.26, 1.93)
4–5 4 (9.8) 0 (0.0) 2.72 (0.77, 9.56)
6–7 7 (17.1) 13 (29.5) 1.43 (0.48, 4.22)
8–19 Most symptoms 8 (19.5) 3 (16.8) 1.38 (0.49, 3.88)
Anxiety score
0–4 Least symptoms 7 (17.1) 7 (15.9) 1.00 Reference
5–7 10 (24.4) 12 (27.3) 1.16 (0.44, 3.10)
8–9 8 (19.5) 6 (13.6) 0.65 (0.20, 2.09)
10–12 9 (22.0) 10 (22.7) 1.05 (0.37, 2.92)
13–19 Most symptoms 7 (17.1) 9 (20.5) 1.25 (0.42, 3.76)
QOL score
13–18 Highest QoL 9 (22.0) 7 (15.9) 1.00 Reference
19–23 7 (17.1) 11 (25.0) 1.62 (0.56, 4.71)
24–26 6 (14.6) 8 (18.2) 1.30 (0.41, 4.14
27–33 11 (26.8) 8 (18.2) 0.61 (0.22, 1.71)
34–36 Lowest QoL 8 (19.5) 10 (22.7) 1.21 (0.42, 3.47)
Felt stigma score
0 Least stigma 12 (29.3) 15 (34.1) 1.00 Reference
1–2 9 (22.0) 10 (22.7) 1.05 (0.37, 2.92)
3–4 8 (19.5) 13 (29.5) 1.73 (0.63, 4.77)
5–9 Most stigma 12 (29.3) 6 (13.6) 0.38 (0.13, 1.15)
Medication management
13–39 Lowest skills 5 (12.5) 11 (25.0) 1.00 Reference
40–44 6 (15.0) 10 (22.7) 1.90 (0.65, 5.54)
45–46 9 (22.5) 10 (22.7) 1.18 (0.44, 3.16)
47–48 8 (20.0) 7 (15.9) 0.93 (0.32, 2.72)
49–50 Highest skills 12 (30.0) 6 (13.6) 0.48 (0.16, 1.41)
Satisfaction info
1–4 Least satisfied 7 (17.5) 7 (16.3) 1.00 Reference
5–7 8 (20.0) 10 (23.3) 1.21 (0.42, 3.48)
8–9 6 (15.0) 9 (20.9) 1.50 (0.48, 4.71)
10–11 8 (20.0) 10 (23.3) 1.21 (0.42, 3.48)
12–17 Most satisfied 11 (27.5) 7 (16.3) 0.51 (0.18, 1.50)
Social knowledge
8–12 Lowest knowledge 10 (24.4) 5 (11.4) 1.00 Reference
13–14 13 (31.7) 13 (29.5) 0.90 (0.36, 2.29)
15–15 9 (22.0) 13 (29.5) 1.49 (0.56, 4.01)
16–20 Highest knowledge 9 (22.0) 13 (29.5) 1.49 (0.56, 4.01)
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Those lost to follow-up differed from those retained in their
baseline characteristics. This, together with unequal loss to follow-
up between treatment groups, further imbalanced the character-
istics of the two groups (Table S2). As well as the ENS group still
having had fewer seizures, at baseline it now comprised fewer
participants who had felt highly stigmatized by epilepsy. At the
same time, fewer TAU group participants had a co-morbid
condition.
Receipt of the ENS intervention. Over the entire 12-month
follow-up period, 35 (80%) of the 44 recruited participants offered
the intervention attended. It is this subgroup of participants who
formed the treatment group for the purposes of the efficacy based
analyses.
Of the 35 participants, 17 (39%) attended 1 ENS session, 12
(27%) 2 sessions and 6 (14%) 3 sessions. The first session took place
on average 5 weeks following recruitment, the second 24 weeks
and the third 38 weeks later. No baseline characteristic was found
to significantly predict whether an intervention participant
received at least one ENS session or not (all P,0.05).
Effect of ENS intervention on clinical outcomes
Unadjusted analyses of effect on ED use. Table 3 presents
the pattern of ED use reported by the two groups. The rate of ED
visits reported by the ENS treatment group at assessment 3 was
55% lower than the TAU comparison groups (Table 4). This
difference was though not statistically significant (P = 0.113), with
group not significantly predicting ED use in the ITT analyses
(Wald X2 (1) = 2.52, P = 0.1127). No significant difference was also
found in the rate of visits reported by the groups at assessment 2
according to the ITT analyses.
No significant effect of the ENS intervention on subsequent ED
visits was found when analyses were restricted to include in the
Table 2. Cont.
Baseline measure (n/ %) Treatment groups at baseline
TAU group (n = 41) ENS group (n = 44) OR (95% CI)
Medical knowledge
15–21 Lowest knowledge 11 (26.8) 7 (15.9) 1.00 Reference
22–24 9 (22.0) 8 (18.2) 0.79 (0.27, 2.31)
25–26 7 (17.1) 8 (18.2) 1.08 (0.35, 3.32)
27–28 7 (17.1) 11 (25.0) 1.62 (0.56, 4.71)
29–32 Highest knowledge 7 (17.1) 10 (22.7) 1.43 (0.48, 4.22)
Mastery
6–12 Lowest confidence 10 (24.4) 8 (18.2) 1.00 Reference
13–14 8 (19.5) 11 (25.0) 1.38 (0.49, 3.88)
15–15 5 (12.2) 8 (18.2) 1.60 (0.47, 5.40)
16–17 8 (19.5) 10 (22.7) 1.21 (0.42, 3.47)
18–21 Highest confidence 10 (24.4) 7 (15.9) 0.59 (0.20, 1.73)
NotesRAED= antiepileptic drug; CI = Confidence interval; ED = Emergency department; ENS= Epilepsy Nurse Specialist; OR = Odds-ratio; Primary care QoF 8 score =
Quality and Outcomes Framework; percentage of people with epilepsy (aged $16) prescribed AEDs in the local population who were seizure free in the previous
12 months as recorded by primary care medical practices in England in 2009/10; QoL = Quality of Life; TAU= Treatment as usual.
P,0.10 shown in bold; Logistic regression used.
doi:10.1371/journal.pone.0090789.t002
Table 3. Emergency department visits for epilepsy reported at baseline and at follow-up assessments.
Emergency department visits n (%)
0 1 2–3 $4
Baseline (visits during prior 12 months)
TAU group (n = 41) 0 15 (36.6) 13 (31.7) 13 (31.7)
ENS group (n = 44) 0 18 (40.9) 15 (34.1) 11 (25.0)
Assessment 2 (visits during prior 6 months)
TAU group (n = 37) 23 (62.2) 6 (16.2) 4 (10.8) 4 (10.8)
ENS group (n = 32) 13 (40.6) 10 (31.3) 7 (21.9) 2 (6.3)
Assessment 3 (visits during prior 6 months)
TAU group (n = 37) 23 (62.2) 4 (10.8) 6 (16.2) 4 (10.8)
ENS group (n = 32) 22 (68.8) 3 (9.4) 6 (18.8) 1 (3.1)
NotesRFrequency of emergency department visits was over-dispersed at both 6- (M 1.12, variance 4.34; X2 (1) = 50.93, P,0.001) and 12-month follow-up (M 1.13
variance 7.65; X2 (1) = 111.65, P,0.001); ENS = Epilepsy Nurse Specialist; TAU = Treatment as usual.
doi:10.1371/journal.pone.0090789.t003
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ENS group only those participants who had received at least one
intervention session (Table S3).
Adjusted analyses of the effect on ED use. The baseline
variables identified by univariate screening as predictive of greater
ED visits following recruitment were, in descending order of
importance, lower confidence in managing epilepsy (less mastery),
higher number of prescribed AEDs, more felt stigma, higher
number of baseline ED visits, greater seizure frequency, and
higher levels of depression and anxiety.
Including these covariates in the regression models for ED visits
resulted in the models now significantly predicting the ED visits
participants reported having made both 6- (Wald X2 (6) = 103.30,
P,0.0001) and 12-months following recruitment (Wald X2 (11) =
140.90, P,0.0001). Treatment group, however, remained a non-
significant predictor when the data was analysed on both an ITT
(Table 4) and an efficacy basis (Table S3). In these multivariate
analyses, it was greater felt stigma and less confidence in managing
epilepsy which emerged as significant predictors of ED visits at
assessment 3 (Table 5).
Table 4. Intention-to-treat analysis comparing treatment groups on primary and secondary outcome measures.
Outcome measure Assessment 2 (n =69) Assessment 3 (n=69)
Unadjusted Adjusted Unadjusted Adjusted
IRR/ Coefficient
(95% CI)
IRR/ Coefficient
(95% CI)
IRR/ Coefficient
(95% CI)
IRR/ Coefficient
(95% CI)
Primary outcome measure
Emergency department visits 1.07 (0.45, 2.54) 1.75 (0.93, 3.28) 0.45 (0.17, 1.20) 1.92 (0.68, 5.41)
Secondary outcome measure
Quality of Life (higher = poorer quality) 1.29 (22.35, 4.94) 0.98 (21.40, 3.36) 2.65 (21.06, 6.37) 3.20 (20.59, 6.98)
Seizure frequency (higher = more seizures) 20.27 (22.30, 1.74) 0.51 (21.10, 2.12) 20.27 (22.19, 1.65) 0.58 (20.97, 2.13)
Anxiety (higher = more symptoms) 20.41 (22.64, 1.83) 21.01 (22.56, 0.55) 21.04 (23.29, 1.20) 21.72 (23.70, 0.25)
Depression (higher = more symptoms) 0.25 (21.68, 2.17) 20.67 (21.94, 0.59) 0.18 (21.72, 2.08) 20.03 (21.88, 1.82)
Medication management skills (higher = better skills) 22.70 (24.63, 0.77) 21.28 (22.94, 0.38) 21.26 (25.50, 2.97) 1.85 (21.47, 44.99)
Mastery (higher = greater confidence) 20.46 (22.14, 1.21) 20.80 (22.23, 0.62) 0.32 (21.33, 1.98) 20.49 (22.10, 1.12)
Epilepsy social knowledge (higher = more knowledgeable) 0.04 (21.18, 1.25) 20.86 (21.82, 0.11) - -
Epilepsy medical knowledge (higher = more
knowledgeable)
0.32 (21.54, 2.17) 20.94 (22.22, 0.34) - -
Felt stigma (higher = more stigmatization) 20.69 (22.03, 0.64) 0.01 (20.85, 0.85) - -
Satisfaction with medication information
(higher = more satisfied)
0.31 (21.43, 0.82) 20.16 (22.40, 2.08) - -
NotesRIRR = incidence rate-ratio; CI = confidence interval; AED = antiepileptic drug; ED Emergency Departments.
P,0.05 shown in bold; Negative binomial regression used for outcome measure emergency visits and linear regression used for all remaining measures.
IRRs less than 1 here represent a lower visit rate in the ENS intervention group relative to TAU group, whilst IRRs greater than 1, indicate a higher rate.
For secondary outcome measures, positive coefficients here indicate an increase in the score on the outcome variable associated with receiving the ENS led self-
management intervention, whilst a negative coefficient the opposite.
Adjustments were made for baseline variables related to outcome at P,0.10:
Emergency department (ED) visits: Baseline Seizure frequency (assessment 3) ED visits (assessments 2, 3), Seizure severity (3), AED number (2,3), Depression (2,3), Anxiety
(2,3), Quality of Life (QoL) (3), Felt stigma (3), Medical knowledge (3), Mastery (2,3). Number of covariates in final assessment 2 model = 5; Number of variables in final
assessment 3 model = 10.
QoL: Baseline Seizure frequency (2,3), ED visits (2,3), AED number (2), Depression (2,3), Anxiety (2, 3), QoL (2,3), Stigma (2,3), Satisfaction medication information (2),
Social knowledge (3), Medical knowledge (3), Mastery (2,3). Number of covariates in final assessment 2 model = 9; Number of covariates in final assessment 3 model = 9.
Seizure frequency: Baseline Seizure frequency (2,3), Primary care seizure-free rate (QOF score 8) (3), Gender (2), ED visits (2,3), Seizure severity (2), AED number (2,3),
Depression (2,3), Anxiety (2,3), QoL (2,3), Felt stigma (2,3), Medication management (2), Social knowledge (3), Mastery (2,3). Number of covariates in final assessment 2
model = 11; Number of covariates in final assessment 3 model = 10.
Anxiety: Baseline Seizure frequency (3), ED visits (2,3), AED number (2), Depression (2,3), Anxiety (2,3), QoL (2,3), Felt stigma (2,3), Social knowledge (3), Mastery (2,3).
Number of covariates in final assessment 2 model = 7; Number of covariates in final assessment 3 model = 8.
Depression: Baseline Age (3), Education (3), Deprivation (3), ED visits (2,3), Depression (2,3), Anxiety (2,3), QoL (2,3), Felt stigma (2,3), Social knowledge (3), Medical
knowledge (3), Satisfaction with medication information (2), Mastery (2,3). Number of covariates in final assessment 2 model = 7; Number of covariates in final
assessment 3 model = 11.
Medication Management Skills: Baseline Age (2), Sex (2), Epilepsy duration (2), AED number (3), Depression (3), Medication Management (3), Medical knowledge (3).
Number of covariates in adjusted assessment 2 model = 3; Number of covariates in final assessment 3 model = 4.
Mastery: Baseline Seizure frequency (2,3), Gender (2), Ethnicity (3), Deprivation (3), ED visits (2,3), Seizure severity (2,3), AED number (2,3), Depression (2,3), Anxiety (2,3),
QoL (2,3), Felt stigma (2,3), Social knowledge (3), Medical knowledge (3), Mastery (2,3). Number of covariates in final assessment 2 model = 10; Number of covariates in
final assessment 3 model = 13.
Epilepsy social knowledge: Baseline Age, Education, Deprivation, Medication management skills, Social knowledge, Medical knowledge. Number of covariates in final
assessment model = 6.
Epilepsy medical knowledge: Baseline Age, Education, Deprivation, ED visits, Depression, Anxiety, Felt stigma, Social knowledge, Medical knowledge, Mastery. Number
of covariates in final assessment model = 10.
Felt stigma: Baseline Seizure frequency, Ethnicity, Deprivation, ED visits, Seizure severity, AED number, Depression, QoL, Felt stigma, Mastery. Number of covariates in
final assessment model = 10.
Satisfaction with medication information: Baseline Primary care QOF 8 score, Deprivation, ED visits, Depression, Anxiety, QoL, Felt stigma, Satisfaction with medication
information, Medical knowledge, Mastery. Number of covariates in final assessment model = 10.
doi:10.1371/journal.pone.0090789.t004
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Effect on patient well-being. No significant effect of the
ENS intervention was found on any of the measures of patient
well-being at the primary, 12-month outcome assessment, both
when analysed on an ITT basis (Table 4) and when analysed using
an efficacy based approach (Table S3).
Cost effectiveness
The mean total service cost over the entire follow-up period was
£2948 for the TAU treatment group and £2202 for the ENS
treatment group (Table 6). The average adjusted difference in
service costs was £558 (95% bootstrapped CI –£2409 to £648)
less for intervention group participants than for TAU participants.
This was accounted for by differences between the groups in their
pattern of service use which were most pronounced during the
initial 6 months of follow-up.
During the initial 6 months, more ENS group participants
visited an ED for epilepsy (57%) compared to the TAU group
(38%), but for those who did the mean number of visits was less
(1.7 vs. 2.9) (Table 5). Also, whilst a similar number of participants
from both treatment groups had hospital admissions, these were
longer for the TAU group. The costs associated with inpatient care
were 527% higher for the TAU group.
The QALY gain over the follow-up period for the ENS
treatment group was 0.786 compared to 0.807 for the TAU group.
The mean difference, adjusting for baseline differences, was
0.0211, which was not statistically significant (bootstrapped 95%
CI, 20.09 to 0.04). Based on the average costs and QALY
difference, the ENS intervention resulted in lower costs but fewer
QALYs. The ICER was 2£558 divided by 20.0211. This means
that it costs an extra £26,445 to achieve one extra QALY if the
ENS intervention is not used.
Discussion
Principal findings
Health service planners need cost-effective interventions to
reduce unnecessary emergency visits by PWE and resulting
admissions. A self-management intervention delivered by an
ENS had been proposed as potentially able to reduce visits. We
compared its clinical- and cost-effectiveness to TAU alone.
Table 5. Association between baseline variables and emergency department visits made by participants over follow-up.
Baseline measure Assessment 2 Assessment 3
Unadjusted IRR
(95% CI)
Adjusted IRR
(95% CI)
Unadjusted IRR
(95% CI)
Adjusted IRR
(95% CI)
Gender (0 = female; 1 =male) 0.69 (0.31, 1.55) - 0.97 (0.30, 3.12) -
Age (years) 0.99 (0.98, 1.02) - 1.01 (0.98, 1.02) -
Ethnicity (0 = White British; 1 = other) 1.30 (0.52, 3.25) - 2.40 (0.84, 6.87) -
Education (years) 0.92 (0.80, 1.06) - 0.94 (0.82, 1.09) -
Deprivation (higher = more deprivation) 0.97 (0.93, 1.01) - 0.99 (0.93, 1.06) -
Co-morbidity (0 = none; 1 = present) 0.94 (0.40, 2.22) - 1.32 (0.45, 3.83) -
Duration of epilepsy (years) 0.99 (0.97, 1.02) - 0.99 (0.97, 1.03) -
Emergency visits in prior 12 months 1.14 (1.10, 1.19) 1.14 (1.03, 1.26) 1.19 (1.10, 1.29) 1.05 (0.92, 1.20)
Quality of life (higher = poor quality of life) 1.04 (0.99, 1.10) - 1.09 (1.02, 1.16) 0.93 (0.86, 1.01)
Seizure frequency 1.09 (0.97, 1.23) - 1.19 (1.03, 1.38) 0.91 (0.80, 1.02)
Primary care QoF 8 score (higher = more seizure free) 1.01 (0.98, 1.03) - 0.98 (0.96, 1.01) -
Seizure severity (higher = more severe) 1.01 (0.99, 1.02) - 1.03 (1.01, 1.04) 1.02 (0.99, 1.03)
Seizure localization (0 = Generalized or
unknown, 1 = Focal)
0.55 (0.24, 1.24) - 0.66 (0.23, 1.96) -
Number of AEDs prescribed 1.56 (1.13, 2.15) 0.98 (0.68, 1.41) 1.69 (1.18, 2.44) 1.43 (0.83, 2.47)
Depression (higher = more symptoms) 1.12 (1.04, 1.20) 0.99 (0.88, 1.12) 1.16 (1.07, 1.25) 0.99 (0.87, 1.14)
Anxiety (higher = more symptoms) 1.13 (1.04, 1.23) 1.02 (0.94, 1.11) 1.10 (0.99, 1.22)
Felt stigma (higher = more felt stigma) 1.14 (1.01, 1.30) 0.97 (0.82, 1.10) 1.42 (1.19, 1.69) 1.32 (1.11, 1.56)
Medication Management Skills (higher = better skills) 0.97 (0.92, 1.03) - 1.01 (0.96, 1.06) -
Satisfaction with information (higher =
increased satisfaction)
0.93 (0.83, 1.04) - 0.89 (0.77, 1.04) -
Medical knowledge (higher = more knowledge) 0.95 (0.87, 1.03) - 0.92 (0.83, 1.02) -
Social knowledge (higher = more knowledge) 0.88 (0.71, 1.09) - 0.80 (0.60, 1.06) -
Mastery (higher = more confidence in managing epilepsy) 0.85 (0.78, 0.93) 0.95 (0.87, 1.04) 0.77 (0.70, 0.84) 0.86 (0.77, 0.96)
Model summary X2 (6) = 43.69, P,0.0001 X2 (8) = 120.91,
P,0.0001
NotesRIRR = incidence rate-ratio; CI = confidence interval; AEDs = antiepileptic drugs; Primary care QoF 8 score = Quality and Outcomes Framework; percentage of
people with epilepsy (aged $16) prescribed AEDs in the local population who were seizure free in the previous 12 months as recorded by primary care medical
practices in England in 2009/10.
P,0.05 shown in bold; Negative binomial regression used.
doi:10.1371/journal.pone.0090789.t005
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Eighty-percent of the participants offered the intervention in our
study attended at least one intervention session. This uptake rate is
favourable when compared to trials of nurse interventions in the
wider epilepsy population [18,40–44]. The ENS-led intervention
did not though lead to a statistically significant benefit in terms of
reducing subsequent visits to ED, nor was there any improvement
on the secondary measures of patient well-being. However,
recruitment into our study was slower than anticipated, and the
study finished with 69 participants instead of the planned 120.
This meant our study was underpowered to detect the hypothe-
sised effect on ED use and there this consequent ambiguity in
some conclusions. The results from our adjusted analyses are,
nevertheless, evidence against the possibility of a large reduction in
ED visits.
Potential reasons why the intervention might not lead to
a large reduction in ED visits
Firstly, whilst previous evidence had suggested a nurse-led
intervention could reduce ED visits [16,17], this came from studies
using weaker methodologies. Studies had compared ED visits in
patients before and after receiving such interventions, but did not
have a TAU comparison group. All reductions in ED visits were,
therefore, attributed to the intervention. As a result of our baseline
study it is now known that even without the support of a nurse,
40% of epilepsy attendees do not revisit an ED in 12 months [10].
We included a TAU group to allow for this.
Secondly, a 2-session ENS intervention which lasts about
90 minutes in total may have been too brief to change self-
management skills. More intensive interventions are used for those
with other chronic, relapsing conditions. For type 1 diabetes, a 5-
day course is used [45]. Indeed, it has been suggested that brief
nurse interventions might serve to underline the label of epilepsy
and adversely heighten a patient’s awareness of epilepsy’s
restricting effects [41]. We though did not find any quantitative
(or qualitative [46]) evidence to support this here, just as Bradley
and Lindsday [47] did not in their Cochrane review of the effect of
nurse interventions in the wider epilepsy population.
Finally, the ENSs tailored the content of intervention sessions to
the needs of individual patients. This meant focus was not
necessarily given to reducing participants’ perceptions of stigma,
their depression and anxiety, seizures, or to improving confidence
in managing epilepsy. The results we have presented here on the
predictors of subsequent ED by participants in our study, and also
in-depth interviews with the participants themselves [48], suggest
these may need to be addressed.
Cost-effectiveness of the ENS intervention
Health economic evaluation provided a somewhat different
perspective on the intervention’s utility. Despite the additional
input from the ENS, the cost of caring for an intervention group
participant was on average £558 less. One reason for this was that
the duration of hospital admissions following ED visits was shorter
for the group who were offered the ENS intervention.
We used the EQ-5D health status questionnaire to calculate the
QALY gain that occurred over follow-up associated with receiving
the two treatments. The gain was slightly less for participants in
ENS group than for those in the TAU group. This was
unexpected, and runs counter to the finding that the more
detailed and specific epilepsy QoL measure which did not show a
difference between the two groups.
Implications for future interventions
Why, after receiving the ENS intervention, participants stayed
for shorter times in hospital following ED visits is unclear.
Potentially the intervention led to a change in these patients’
epilepsies that was not captured by our measures. For example, we
did not assess seizure severity at follow-up. Future studies should
consider this.
Previous models for ED use have focused on seizure frequency
and only found a modest association between this single measure
of disease severity and ED use [49]. Using multiple regression, we
found that it was the degree to which patients felt stigmatized by
epilepsy at baseline and, to a lesser extent, their confidence in
managing epilepsy best predicted subsequent ED use. Our study is
the first to provide longitudinal evidence on these variables’
importance. This suggests felt stigma may be a driver of ED use
and not simply a consequence [10].
How felt stigma and mastery influence ED use and what sort of
intervention can modify them requires further investigation. We
acknowledge that felt stigma may have emerged as a key predictor
of ED use because it is a marker of disease severity, capturing more
aspects of severity than other candidate variables. Indeed, the
wider epilepsy literature consistently shows that felt stigma is
associated with seizure frequency, epilepsy duration, number of
AEDs, psychological distress and QoL. More complex statistical
modelling by future studies could help further clarify felt stigma’s
role in ED use.
With regards optimization of the intervention, findings from
interviews with our participants reported elsewhere [48] suggests
that it might be appropriate for future interventions to systemat-
ically involve patients’ significant others and offer them first aid
training. Responsibility for patient care is often delegated to these
persons when seizures occur.
Limitations
Our study makes an important contribution to a small body of
research. Its results though should be interpreted in light of some
limitations.
Firstly, treatment allocation was not randomized. We did not
receive funding to do this. Unknown baseline differences may have
existed between our treatment groups, and this may reduce the
accuracy of our treatment effect estimate. We did though seek to
minimize the likelihood of differences by restricting recruitment to
PWE from similar hospitals and areas. We also endeavoured to
capture any differences by using a wide selection of baseline
measures and adjusting for differences detected. We also used
prospective recruitment. This can make estimates from non-
randomized trials similar to those of randomized trials [50].
A second potential limitation is that 27% of those invited to
participate agreed. It is now apparent that such rates are usual
with ED attendees and in studies where serial assessment is
required [45,51]. Low acceptance does, nevertheless, raise the
possibility that participants may not be representative. We have
previously described how our participants’ characteristics were
generally comparable to those of nonparticipants [10].
The lower than anticipated uptake into the study by participants
meant that our sample size was smaller than would have been
preferred for the execution of our analysis plan. It meant that the
case-variable ratio for our regression analyses was typically below
the recommended 10 cases per variable rule [52]. For our adjusted
ITT models, the median ratio was 6.6 (IQR 6.3–9.0). Conse-
quently, some of our final regression models may be overfitted. It
remains to be seen how well our findings are replicated by future,
larger studies.
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Thirdly, we recruited from an urban, ethnically diverse
population with high social deprivation. Low educational attain-
ment may reduce the ability of a brief intervention to influence
outcome. It may also limit our results’ generalizability to rural, less
deprived populations. However, the potential similarity of our
multi-ethnic population to those in metropolitan areas in the UK
and beyond may make our evidence internationally generalizable.
Further facilitating this is that the U.K. health service is publicly
funded like those in most western countries.
At follow-up, we retained 81% of participants. This is
favourable compared to previous studies [47,53,54]. Those lost
were though more likely to have felt highly stigmatised at baseline
and have been in the ENS treatment group. This may further limit
the accuracy of our treatment estimate.
Finally, the researcher administering assessments was not blind
to participants’ treatment group. This may have influenced the
assessments in some way, even though the same scoring
procedures were followed for each participant, and the outcome
negative.
Conclusions
We tested an ENS-led intervention that aimed to reduce costly
ED visits by PWE. A comparison to TAU alone, found no
significant benefit on ED visits 6- and 12-months post-recruitment.
No effects on the secondary psychosocial measures were also
found. It did though slightly reduce total health care costs. This is
the first study of an intervention for PWE who attend ED. Novel
results from our analyses of long-term predictors of subsequent ED
use suggest that to reduce visits, interventions should focus more
on patients’ perceptions of stigmatization due to epilepsy, and
confidence managing epilepsy.
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